746
Views
14
CrossRef citations to date
0
Altmetric
Research Article

QSAR of aminopyrido[2,3-d]pyrimidin-7-yl derivatives: Anticancer drug design by computed descriptors

&
Pages 937-948 | Received 11 Jul 2008, Accepted 09 Sep 2008, Published online: 07 Apr 2009
 

Abstract

A series of aminopyrido[2,3-d]pyrimidin-7-yl derivatives acting as potential tyrosine kinase inhibitors having anticancer activities have been considered in the present investigation for the quantitative structure-activity relationship studies based on 2D and 3D QSAR approaches. For this purpose, various theoretical molecular descriptors were computed solely from the structures of these compounds. As the number of molecular descriptors greatly exceeds the number of observations, conventional regression does not produce reliable models and therefore, ridge regression methodology was used to solve this problem. The influence of different classes of molecular descriptors on the activity has been predicted and the most significant descriptors were obtained using the ridge regression models. Partial least squares (PLS) models were developed based on the training set for the 3D QSAR models of the above compounds. The influences of steric and electrostatic field effects generated by the contribution plots are discussed.

Declaration of interest: Sisir Nandi thanks the Council of Scientific and Industrial Research, New Delhi 110001, India for the grant of a Senior Research Fellowship.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.